Brasília – A new Brazilian study evaluated the lifetime costs and outcomes of an advanced cancer therapy priced at around R$ 3 million per patient. Researchers found that when the treatment is used earlier in the disease cours, rather than as a last-resort optio, it may lead to better survival outcomes and lower cost per life-year gained compared to traditional care.

The analysis indicated that earlier intervention significantly reduces downstream expenses such as hospital admissions, intensive-care use, and complications related to late-stage cancer. According to the study, this approach could transform high-cost therapies from being viewed solely as expensive options into economically sustainable innovations within the public-health system.

Source: G1

Want to explore this and other key issues in Brazil’s health system?
Contact us at pharmabrnews@gmail.com